Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide. |
| Methoxy polyethylene glycol-epoetin beta | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide is combined with Lidocaine. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide is combined with Ropivacaine. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide is combined with Bupivacaine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide is combined with Cinchocaine. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide is combined with Dyclonine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide is combined with Procaine. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide is combined with Prilocaine. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide is combined with Proparacaine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide is combined with Meloxicam. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide is combined with Oxybuprocaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide is combined with Cocaine. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide is combined with Mepivacaine. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide is combined with Levobupivacaine. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide is combined with Diphenhydramine. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide is combined with Benzocaine. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide is combined with Chloroprocaine. |
| Phenol | The risk or severity of methemoglobinemia can be increased when 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide is combined with Phenol. |
| Tetrodotoxin | The risk or severity of methemoglobinemia can be increased when 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide is combined with Tetrodotoxin. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide is combined with Benzyl alcohol. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide is combined with Capsaicin. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide is combined with Etidocaine. |
| Articaine | The risk or severity of methemoglobinemia can be increased when 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide is combined with Articaine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide is combined with Tetracaine. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide is combined with Propoxycaine. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide is combined with Pramocaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide is combined with Butamben. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide is combined with Butacaine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide is combined with Oxetacaine. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide is combined with Ethyl chloride. |
| Butanilicaine | The risk or severity of methemoglobinemia can be increased when 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide is combined with Butanilicaine. |
| Metabutethamine | The risk or severity of methemoglobinemia can be increased when 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide is combined with Metabutethamine. |
| Quinisocaine | The risk or severity of methemoglobinemia can be increased when 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide is combined with Quinisocaine. |
| Nelarabine | The risk or severity of adverse effects can be increased when Nelarabine is combined with 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide. |
| Ambroxol | The risk or severity of methemoglobinemia can be increased when 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide is combined with Ambroxol. |
| Etrasimod | The risk or severity of immunosuppression can be increased when 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide is combined with Etrasimod. |